CD123-CODV-TCE

CD123-CODV-TCE (also known as SAR440340) is a bispecific T-cell engager (TCE) developed by Sanofi for the treatment of acute myeloid leukemia (AML). It utilizes Sanofi's proprietary Cross-Over-Dual-Variable-Domain (CODV) format, which is engineered onto a humanized IgG1 antibody backbone with a silenced Fc region to minimize non-specific T-cell activation and cytokine release. The molecule is designed to simultaneously bind to CD3 on T cells and CD123 (the alpha chain of the interleukin-3 receptor) on leukemic blasts and leukemic stem cells (LSCs). This dual binding facilitates the formation of an immunological synapse, leading to T-cell activation and the subsequent release of cytotoxic granules, such as granzyme B and perforin, to induce the lysis of CD123-expressing cancer cells. While it demonstrated potent preclinical activity and specific killing of primary AML cells regardless of antigen density, Sanofi terminated the clinical development of the SAR440340 program in early 2022.

Other names

CD3xCD123 Bi-Specific T-Cell EngagerCD-3xCD123 Bi-Specific T-Cell EngagerCD 3xCD123 Bi-Specific T-Cell EngagerCD3-CD123 bispecific T-cell engagerCD-3-CD123 bispecific T-cell engagerCD 3-CD123 bispecific T-cell engagerCD123 CODV-TCECD-123 CODV-TCECD 123 CODV-TCE